|Bid||112.00 x 1800|
|Ask||0.00 x 1200|
|Day's Range||111.67 - 114.30|
|52 Week Range||73.69 - 116.61|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019|
|Forward Dividend & Yield||2.25 (2.01%)|
|1y Target Est||113.00|
It's been frustrating market for growth investors, but the savviest ones continue to build their watch lists with top stocks acting well.
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
Eli Lilly and Co is considering the sale of an off-patent drugs portfolio in China, Bloomberg reported on Friday, citing sources. The assets, which include antibiotics and treatments for central nerve ...
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Indianapolis-based Lilly is working with advisers to gauge interest in a selection of older drugs for antibiotics and central nervous system diseases in China, the people said, asking not to be identified because the matter is private. The portfolio could fetch $200 million to $300 million, the people said.
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
For 2018 and 2019, Clovis Oncology (CLVS) is expected to generate revenues of $88.79 million and $165.13 million, respectively, compared to its revenue of $55.51 million in 2017.
Clovis Oncology (CLVS) incurred selling, general, and administrative expenses of $42.49 million in the third quarter compared to $35.01 million in the third quarter of 2017. This increase was due to higher commercialization activities for Rubraca and preparation for its expected launch in Europe.
Eli Lilly (LLY) files NDA with FDA for migraine candidate, lasmiditan. FDA grants Breakthrough Therapy status to Emgality for episodic cluster headache indication.
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.
Eli Lilly & Co. announced early Wednesday that it has made progress on two migraine therapies, including submitting an application for one medication -- intended for in-the-moment pain relief for migraines -- to the U.S. Food and Drug Administration. If that drug, lasmiditan, is approved, "it could represent the first significant innovation for the acute treatment of migraine in more than two decades," Eli Lilly said. The drugmaker also said that the FDA had granted a "breakthrough therapy" designation to the company's therapy Emgality to prevent episodic cluster headaches; the designation is geared at speeding the development and review of innovative drugs. Emgality was approved in late September to prevent migraines, one of a number of new preventive migraine treatments; cluster headache is another, rare type of headache disorder. There are currently no approved preventive therapies for the condition in the U.S., according to Eli Lilly, and the company plans to submit an application to the FDA by the end of the year. Company shares were inactive in premarket trade. Shares have risen 9.2% over the last three months, compared with a 3.5% decline in the S&P 500 .
INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults. Lasmiditan is an investigational, oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies and lacks vasoconstrictive activity.
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of June 30. In this article, we look at what those funds think of Eli Lilly & Co. (NYSE:LLY) based on […]
Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.
Eli Lilly is the IBD Stock Of The Day as the Big Pharma giant approaches a buy point on excitement for its diabetes treatments.
After Democrats obtained a narrow majority in the House of Representatives in the midterm elections, both House Democrats and President Trump will likely be looking to make at least some deals. To retain their majority, House Democrats will have to convince moderate voters in the swing districts that Democrats narrowly won that they are moderate and can be productive. For his part, President Trump will likely have to convince at least some moderate voters, i.e., centrist suburban women and independents that he can make deals that will make the country and their lives better.